The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Abstract
CONTEXT: The alpha4beta2 nicotinic acetylcholine receptors (nAChRs) are linked to the reinforcing effects of nicotine and maintaining smoking behavior. Varenicline, a novel alpha4beta2 nAChR partial agonist, may be beneficial for smoking cessation. OBJECTIVE: To assess efficacy and safety of varenicline for smoking cessation compared with sustained-release bupropion (bupropion SR) and placebo. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, parallel-group, placebo- and active-treatment-controlled, phase 3 clinical trial conducted at 19 US centers from June 19, 2003, to April 22, 2005. Participants were 1025 generally healthy smokers (> or =10 cigarettes/d) with fewer than 3 months of smoking abstinence in the past year, 18 to 75 years old, recruited via advertising. INTERVENTION: Participants were randomly assigned in a 1:1:1 ratio to receive brief counseling and varenicline titrated to 1 mg twice per day (n = 352), bupropion SR titrated to 150 mg twice per day (n = 329), or placebo (n = 344) orally for 12 weeks, with 40 weeks of nondrug follow-up. MAIN OUTCOME MEASURES: Primary outcome was the exhaled carbon monoxide-confirmed 4-week rate of continuous abstinence from smoking for weeks 9 through 12. A secondary outcome was the continuous abstinence rate for weeks 9 through 24 and weeks 9 through 52. RESULTS: For weeks 9 through 12, the 4-week continuous abstinence rates were 44.0% for varenicline vs 17.7% for placebo (odds ratio [OR], 3.85; 95% confidence interval [CI], 2.70-5.50; P<.001) and vs 29.5% for bupropion SR (OR, 1.93; 95% CI, 1.40-2.68; P<.001). Bupropion SR was also significantly more efficacious than placebo (OR, 2.00; 95% CI, 1.38-2.89; P<.001). For weeks 9 through 52, the continuous abstinence rates were 21.9% for varenicline vs 8.4% for placebo (OR, 3.09; 95% CI, 1.95-4.91; P<.001) and vs 16.1% for bupropion SR (OR, 1.46; 95% CI, 0.99-2.17; P = .057). Varenicline reduced craving and withdrawal and, for those who smoked while receiving study drug, smoking satisfaction. No sex differences in efficacy for varenicline were observed. Varenicline was safe and generally well tolerated, with study drug discontinuation rates similar to those for placebo. The most common adverse events for participants receiving active-drug treatment were nausea (98 participants receiving varenicline [28.1%]) and insomnia (72 receiving bupropion SR [21.9%]). CONCLUSION: Varenicline was significantly more efficacious than placebo for smoking cessation at all time points and significantly more efficacious than bupropion SR at the end of 12 weeks of drug treatment and at 24 weeks. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00141206.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Varenicline, a nicotinic acetylcholine receptor (nAChR) partial agonist, is reported to increase continuous abstinence rates to ∼50% following 12 weeks of treatment, which is significantly better than bupropion (∼30%) or placebo (∼18%”
From Parallel Anxiolytic-Like Effects and Upregulation of Neuronal Nicotinic Acetylcholine Receptors Following Chronic Nicotine and Varenicline (2011) · cites this paper as Gonzales et al., 2006
In the citing paper
“Varenicline, a partial agonist at the α4β2 nAChRs, and a full agonist at the α7 nAChRs, is a new, efficacious treatment for nicotine dependence (4–6).”
From Varenicline improves mood and cognition during smoking abstinence (2009) · cites this paper as [4]
In the citing paper
“These trials document treatment-related reductions in smoking urges and withdrawal-related negative affect (4, 5, 9), as well as reduced smoking reward during a lapse (10).”
From Varenicline improves mood and cognition during smoking abstinence (2009) · cites this paper as [4]
In the citing paper
“The effects of varenicline on subjective abstinence symptoms were of a magnitude similar to those observed in clinical efficacy trials (4, 36).”
From Varenicline improves mood and cognition during smoking abstinence (2009) · cites this paper as [4]
In the citing paper
“Individuals who relapsed derived less enjoyment from smoking while taking varenicline [241].”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [241]
In the citing paper
“Nearly one quarter (21–23%) of patients taking varenicline for a short period of time (12 weeks) maintained abstinence at 52 weeks of follow-up.”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [241]
In the citing paper
“Gonzales and colleagues [241] found a similar decrease in negative affect, but also found a significant decrease in restlessness in patients taking varenicline.”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [241]
In the citing paper
“This represents a significant improvement over sustained-release bupropion (14–16%) and placebo (8–10%).”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [241]
In the citing paper
“Two large, randomized, placebo-controlled studies released in 2006 related the efficacy of varenicline to that of bupropion in aided smoking cessation [233, 241].”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [241]
In the citing paper
“numerous studies have shown that varenicline, a Food and Drug Administration-approved drug widely used to help people quit smoking, potently acts as a partial agonist at ␣42* nAChRs”
From Varenicline Is a Potent Partial Agonist at α6β2* Nicotinic Acetylcholine Receptors in Rat and Monkey Striatum (2012) · cites this paper as Gonzales et al., 2006
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire
HEATHERTON, T. F., KOZLOWSKI, L. T., FRECKER, R. C., & FAGERSTROM, K. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01879.x · Cited by 10,738
Signs and Symptoms of Tobacco Withdrawal
Hughes, J. R. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800030107013 · Cited by 1,669
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585
Cigarette Smoking Among Adults--United States, 2003
(2005) · JAMA · doi:10.1001/jama.294.2.172 · Cited by 1,520
Cox, L. S., Tiffany, S. T., & Christen, A. G. (2001) · Nicotine & Tobacco Research · doi:10.1080/14622200020032051 · Cited by 1,188
Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs.
Pontieri, F. E., Tanda, G., Orzi, F., & Chiara, G. D. (1996) · Nature · doi:10.1038/382255a0 · Cited by 1,073
Jasinski, D. R. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280111012 · Cited by 782
Fiore, M. (2000) · Respiratory care · doi:10.1177/002013240004501006 · Cited by 773
Cited by
Sorted by citations
Items 501–600 of 1,000
Igarashi, A., Goto, R., Suwa, K., Yoshikawa, R., Ward, A. J., & Möller, J. (2015) · Applied Health Economics and Health Policy · doi:10.1007/s40258-015-0204-3 · Cited by 30
Therapy Insight: peripheral arterial disease and diabetes—from pathogenesis to treatment guidelines
Mohler, E. R. (2007) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0823 · Cited by 30
Bolin, K., Mörk, A., & Wilson, K. (2009) · Journal of Evaluation in Clinical Practice · doi:10.1111/j.1365-2753.2008.01045.x · Cited by 29
Smoking cessation therapy with varenicline
Krishna, G. (2008) · International Journal of COPD · doi:10.2147/copd.s1848 · Cited by 28
Patientsʼ Attitudes towards Generic Substitution of Oral Atypical Antipsychotics
Roman, B. (2009) · CNS Drugs · doi:10.2165/00023210-200923080-00003 · Cited by 28
Pathological Video Gaming and Its Relationship to Substance Use Disorders
Smith, K. L., Hummer, T. A., & Hulvershorn, L. A. (2015) · Current Addiction Reports · doi:10.1007/s40429-015-0075-6 · Cited by 28
Systematic review of the cost-effectiveness of varenicline vs. bupropion for smoking cessation
Mahmoudi, M., Coleman, C. I., & Sobieraj, D. M. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02877.x · Cited by 28
Smoking cessation: present status and future perspectives
Caponnetto, P., Russo, C., & Polosa, R. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.02.005 · Cited by 30
Smoking Cessation: An Overview of Treatment Options with a Focus on Varenicline
Stack, N. M. (2007) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.11.1550 · Cited by 28
Update on pharmacologic and nonpharmacologic therapies for smoking cessation.
Schmelzle, J., Rosser, W., & Birtwhistle, R. (2008) · Europe PMC (PubMed Central) · Cited by 28
Benli, A. R., Erturhan, S., Oruç, M. A., Kalpakci, P., Sunay, D., & Demirel, Y. (2017) · Tobacco Induced Diseases · doi:10.1186/s12971-017-0116-0 · Cited by 28
The effects of varenicline on stress-induced and cue-induced craving for cigarettes
Ray, L. A., Lunny, K., Bujarski, S., Moallem, N., Krull, J. L., & Miotto, K. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.12.015 · Cited by 27
Abstinence and psychological distress in co-morbid smokers using various pharmacotherapies
Steinberg, M. B., Manderski, M. T. B., Richardson, D. L., Schmelzer, A. C., Williams, J. M., & Foulds, J. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.06.022 · Cited by 27
Ni, K., Wang, B., Link, A. R., & Sherman, S. E. (2018) · Nicotine & Tobacco Research · doi:10.1093/ntr/nty257 · Cited by 27
Zhong, Z., Zhao, S., Zhao, Y., & Xia, S. (2019) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2019.152125 · Cited by 27
Heffner, J. L., Lee, T. C., Arteaga, C., & Anthenelli, R. M. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.12.022 · Cited by 27
Vemer, P., & Mölken, M. R. (2009) · Value in Health · doi:10.1111/j.1524-4733.2009.00612.x · Cited by 27
Paterson, N. E. (2009) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32832c7083 · Cited by 27
Titomanlio, F., Perfumi, M. C., & Mattioli, L. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3351-y · Cited by 27
Effectiveness of varenicline for smoking cessation: A 1-year follow-up study
Grassi, M., Enea, D., Ferketich, A. K., Lü, B., Pasquariello, S., & Nencini, P. (2011) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2011.01.014 · Cited by 27
Organic Cation Transporter Variation and Response to Smoking Cessation Therapies
Bergen, A. W., Javitz, H. S., Krasnow, R. E., Michel, M., Nishita, D., Conti, D. V., Edlund, C. K., Kwok, P., McClure, J. B., Kim, R. B., et al. (2014) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntu161 · Cited by 27
Effects of continued tobacco use during treatment of lung cancer
Waller, L. L., Weaver, K. E., Petty, W. J., & Miller, A. A. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.140 · Cited by 27
Orthosteric and Allosteric Ligands of Nicotinic Acetylcholine Receptors for Smoking Cessation
Mohamed, T. S., Jayakar, S. S., & Hamouda, A. K. (2015) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2015.00071 · Cited by 27
Gray, J. E., Mao, J. T., Szabo, E. M., Kelley, M. J., Kurie, J. M., & Bepler, G. (2007) · CHEST Journal · doi:10.1378/chest.07-1348 · Cited by 26
Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Type 2 Diabetes
Russo, C., Walicka, M., Caponnetto, P., Cibella, F., Maglia, M. G., Alamo, A., Campagna, D., Frittitta, L., Mauro, M. D., Caci, G., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.17709 · Cited by 26
Worsening Psychosis Induced by Varenicline in a Hospitalized Psychiatric Patient
DiPaula, B. A., & Thomas, M. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.7.852 · Cited by 26
Calverley, P. M. A. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.362 · Cited by 26
Lange‐Asschenfeldt, C., Schäble, S., Suvorava, T., Gholamreza-Fahimi, E., Bisha, M., Stermann, T., Henning, U., & Kojda, G. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.025 · Cited by 26
Foa, E. B., Asnaani, A., Rosenfield, D., Zandberg, L. J., Gariti, P., & Imms, P. (2017) · Journal of Consulting and Clinical Psychology · doi:10.1037/ccp0000213 · Cited by 26
Cinciripini, P. M., Minnix, J. A., Green, C. E., Robinson, J. D., Engelmann, J. M., Versace, F., Wetter, D. W., Shete, S. S., & Karam‐Hage, M. (2018) · Addiction · doi:10.1111/add.14250 · Cited by 28
Nicotine Use Disorders in Adolescents
Cavallo, D. A., & Krishnan‐Sarin, S. (2019) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2019.08.002 · Cited by 26
Efficacy of Drug Therapy in the Secondary Prevention of Cardiovascular Disease and Stroke
Fletcher, G. F., Bufalino, V. J., Costa, F., Goldstein, L. B., Jones, D., Smaha, L. A., Smith, S. C., & Stone, N. J. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.02.001 · Cited by 27
Treating Tobacco Dependence: Review of the Best and Latest Treatment Options
Ebbert, J. O., Sood, A., Hays, J. T., Dale, L. C., & Hurt, R. D. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318031bca4 · Cited by 26
An update on therapeutics for tobacco dependence
Lancaster, T., Stead, L. F., & Cahill, K. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.1.15 · Cited by 26
Leeman, R. F., Huffman, C., & O’Malley, S. S. (2007) · Alcohol and Alcoholism · doi:10.1093/alcalc/agm022 · Cited by 26
Smoking cessation: lessons learned from clinical trial evidence
Reid, R. D., Quinlan, B., Riley, D. L., & Pipe, A. (2007) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e328236740a · Cited by 26
Rennard, S. I., & Daughton, D. M. (2014) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2013.11.002 · Cited by 25
Boudrez, H., Gratziou, C., Messig, M., & Metcalfe, M. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.557718 · Cited by 25
Yousefi, M. K., & Folsom, T. D. (2012) · Journal of Addiction Research & Therapy · doi:10.4172/2155-6105.s4-001 · Cited by 26
Treating depressed and anxious smokers in smoking cessation programs.
Richards, C. S., Cohen, L. M., Morrell, H. E. R., Watson, N. L., & Low, B. E. (2012) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0027793 · Cited by 27
Zeng, F., Chen, C.-I., Mastey, V., Zou, K. H., Harnett, J., & Patel, B. V. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.02.013 · Cited by 25
Janes, A. C., Jensen, J. E., Farmer, S. L., Frederick, B. B., Pizzagalli, D. A., & Lukas, S. E. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.10 · Cited by 25
Adams, T. R., Arnsten, J. H., Ning, Y. M., & Nahvi, S. (2017) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2017.1370746 · Cited by 25
Genetic Analysis of Lung Cancer and the Germline Impact on Somatic Mutation Burden
Gabriel, A. A., Atkins, J., Penha, R. C. C., Smith-Byrne, K., Gaborieau, V., Voegele, C., Abedi‐Ardekani, B., Milojevic, M., Olaso, R., Meyer, V., et al. (2022) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djac087 · Cited by 26
Cancer of the Lung: Non-Small Cell Lung Cancer and Small Cell Lung Cancer
Johnson, D. H., Blot, W. J., Carbone, D. P., González, A., Hallahan, D. E., Massion, P. P., Putnam, J. B., & Sandler, A. B. (2008) · Elsevier eBooks · doi:10.1016/b978-0-443-06694-8.50080-4 · Cited by 25
Ponciano‐Rodríguez, G., Páez-Martı́nez, N., Villa-Romero, A. R., Gutiérrez-Grobe, Y., & Méndez‐Sánchez, N. (2014) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2014.0007 · Cited by 25
Mashhoon, Y., Janes, A. C., Jensen, J. E., Prescot, A. P., Pachas, G. N., Renshaw, P. F., D, M. F. M., Evins, A. E., & Kaufman, M. J. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.05.006 · Cited by 25
Severance, E. G., & Yolken, R. H. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.06.008 · Cited by 25
Kotz, D., Brown, J., & West, R. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3202-x · Cited by 24
Effect of high-dose nicotine patch on the characteristics of lapse episodes.
Ferguson, S. G., & Shiffman, S. S. (2010) · Health Psychology · doi:10.1037/a0019367 · Cited by 24
Chang, P.-Y., Lo, P.-C., Chang, H.-C., Hsueh, K.-C., & Tsai, Y. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166992 · Cited by 25
Pérez-Páramo, Y. X., & Lazarus, P. J. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1863948 · Cited by 25
King, A. C., Vena, A. A., de Wit, H., Grant, J. E., & Cao, D. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.0951 · Cited by 24
Stack, A. G., & Murthy, B. V. R. (2010) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2010.00728.x · Cited by 24
Javitz, H. S., Zbikowski, S. M., Deprey, M., McAfee, T. A., McClure, J. B., Richards, J. A., Catz, S. L., Jack, L. M., & Swan, G. E. (2010) · Translational Behavioral Medicine · doi:10.1007/s13142-010-0009-8 · Cited by 24
Pharmacologic Therapy: Novel Approaches for Chronic Obstructive Pulmonary Disease
Bailey, W. C., & Tashkin, D. P. (2007) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200701-017fm · Cited by 24
Subiah, C. O., Mabandla, M. V., Phulukdaree, A., Chuturgoon, A. A., & Daniels, W. M. U. (2012) · Metabolic Brain Disease · doi:10.1007/s11011-012-9297-7 · Cited by 24
Functional network connectivity predicts treatment outcome during treatment of nicotine use disorder
Wilcox, C., Calhoun, V., Rachakonda, S., Claus, E., Littlewood, R. A., Mickey, J., Arenella, P., & Hutchison, K. (2017) · Psychiatry research. Neuroimaging · doi:10.1016/j.pscychresns.2017.04.011 · Cited by 22
Effects of varenicline on alcohol cue reactivity in heavy drinkers
Roberts, W., Harrison, E. L., & McKee, S. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4667-9 · Cited by 20
Treatment adherence and short-term outcomes of smoking cessation outpatient clinic patients
Karadoğan, D., Önal, Ö., Şahin, D. S., Kanbay, Y., Alp, S., & Şahin, Ü. (2018) · Tobacco Induced Diseases · doi:10.18332/tid/94212 · Cited by 24
Ravva, P., Gastonguay, M. R., French, J. L., Tensfeldt, T. G., & Faessel, H. M. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.282 · Cited by 24
Acceptance of cravings: How smoking cessation experiences affect craving beliefs
Nosen, E., & Woody, S. R. (2014) · Behaviour Research and Therapy · doi:10.1016/j.brat.2014.05.003 · Cited by 26
Impact of early nausea on varenicline adherence and smoking cessation
Peng, A. R., Swardfager, W., Benowitz, N. L., Ahluwalia, J. S., Lerman, C. E., Nollen, N. L., & Tyndale, R. F. (2019) · Addiction · doi:10.1111/add.14810 · Cited by 23
Discriminative Stimulus Effects of Nicotine in Humans
Perkins, K. A. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-69248-5_13 · Cited by 23
Enger, C. L., Younus, M., Petronis, K. R., Mo, J., Gately, R. V., & Seeger, J. D. (2013) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3400 · Cited by 23
Perkins, K. A., Mercincavage, M., Fonte, C. A., & Lerman, C. E. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1816-9 · Cited by 23
Getsios, D., Marton, J. P., Revankar, N., Ward, A. J., Willke, R. J., Rublee, D. A., Ishak, K. J., & Xenakis, J. G. (2013) · PharmacoEconomics · doi:10.1007/s40273-013-0070-5 · Cited by 23
Smoking cessation pharmacotherapy
Frishman, W. H. (2009) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944709335754 · Cited by 24
Increasing Varenicline Dose in Smokers Who Do Not Respond to the Standard Dosage
Hájek, P., McRobbie, H. J., Smith, K., Phillips, A. C., Cornwall, D., & Dhanji, A. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.6916 · Cited by 23
Kasza, K. A., Cummings, K. M., Carpenter, M. J., Cornelius, M. E., Hyland, A. J., & Fong, G. T. (2014) · Addiction · doi:10.1111/add.12778 · Cited by 23
Biazzo, L. L., Froshaug, D. B., Harwell, T. S., Beck, H. N., Haugland, C., Campbell, S. L., & Helgerson, S. D. (2010) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntq045 · Cited by 23
Varenicline-Induced Elevation of Dopamine in Smokers: A Preliminary [11C]-(+)-PHNO PET Study
Ciano, P. D., Guranda, M., Lagzdins, D., Tyndale, R. F., Gamaleddin, I., Selby, P. L., Boileau, I., & Foll, B. L. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.305 · Cited by 23
Hurt, R. T., Croghan, I. T., Schroeder, D. R., Hays, J. T., Choi, D., & Ebbert, J. O. (2016) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntw304 · Cited by 23
Harrison, E., Biswas, L., Avusula, R., Zhang, M., Gong, Y., & Liu, X. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4736-0 · Cited by 23
Mao, R. L., Tromeur, C., Paleiron, N., Sanchez, O., Gagnadoux, F., Jouneau, S., Magnan, A., Vannimenus, C., Dansou, A., Proust, A., et al. (2019) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.1080/15412555.2019.1703928 · Cited by 23
Xi, Z. (2010) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s6299 · Cited by 26
Wise, R. A., & Tashkin, D. P. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.04.008 · Cited by 23
McCaul, M. E., Wand, G. S., Kuwabara, H., Dannals, R. F., Wong, D. F., & Xu, X. (2019) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntz080 · Cited by 24
The Black Book of Psychotropic Dosing and Monitoring
DeBattista, C., & Schatzberg, A. F. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4493 · Cited by 23
Mental health stability in veterans with posttraumatic stress disorder receiving varenicline
Campbell, A. R., & Anderson, K. D. (2010) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp100196 · Cited by 22
Gray, K. M., McClure, E. A., Baker, N. L., Hartwell, K. J., Carpenter, M. J., & Saladin, M. E. (2015) · Addiction · doi:10.1111/add.12895 · Cited by 22
Kotz, D., Fidler, J. A., & West, R. (2011) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntr075 · Cited by 22
The influence of sleep quality on smoking cessation in socioeconomically disadvantaged adults
Peltier, M. R., LEE, J., Ma, P., Businelle, M. S., & Kendzor, D. E. (2016) · Addictive Behaviors · doi:10.1016/j.addbeh.2016.11.004 · Cited by 22
Ueta, C. B., Gomes, M. K., Ribeiro, M. A. C., Mochly‐Rosen, D., & Ferreira, J. C. B. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.11.016 · Cited by 22
Waeiss, R. A., Knight, C. P., Hauser, S. R., Pratt, L. A., McBride, W. J., & Rodd, Z. A. (2019) · Psychopharmacology · doi:10.1007/s00213-019-5174-y · Cited by 22
Coe, J. W., Rollema, H., & O’Neill, B. T. (2009) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(09)04404-2 · Cited by 22
Current pharmacologic treatments for smoking cessation and new agents undergoing clinical trials
Nagano, T., Katsurada, M., Yasuda, Y., Kobayashi, K., & Nishimura, Y. (2019) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466619875925 · Cited by 23
Blak, B. T., Wilson, K., Metcalfe, M., Maguire, A., & Hards, M. (2010) · Current Medical Research and Opinion · doi:10.1185/03007990903526461 · Cited by 22
Ramon, J. M., & Bruguera, E. (2009) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph6041530 · Cited by 22
Role of β2-containing nicotinic acetylcholine receptors in auditory event-related potentials
Rudnick, N. D., Koehler, C., Picciotto, M. R., & Siegel, S. J. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1358-6 · Cited by 22
Depression and smoking cessation: Does the evidence support psychiatric practice?
Lembke, A., Johnson, K., & DeBattista, C. (2007) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.a919 · Cited by 22
Olanzapine reduces urge to smoke and nicotine withdrawal symptoms in community smokers.
Rohsenow, D. J., Tidey, J. W., Miranda, R., McGeary, J. E., Swift, R. M., Hutchison, K. E., Sirota, A. D., & Monti, P. M. (2008) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.16.3.215 · Cited by 22
Wang, C., Cho, B.-K., Xiao, D., Wajsbrot, D., & Park, P. W. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12121 · Cited by 21
Nakamura, M., Oshima, A., Ohkura, M., Arteaga, C., & Suwa, K. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.03.013 · Cited by 21
Operating on Patients Who Smoke: A Survey of Thoracic Surgeons in the United States
Marino, K., Little, M. A., Bursac, Z., Sullivan, J. L., Klesges, R. C., & Weksler, B. (2016) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2016.03.076 · Cited by 21
A Discrete-Event Simulation of Smoking-Cessation Strategies Based on Varenicline Pivotal Trial Data
Xenakis, J. G., Kinter, E. T., Ishak, K. J., Ward, A. J., Marton, J. P., Willke, R. J., Davies, S., & Jaime, J. (2011) · PharmacoEconomics · doi:10.2165/11589230-000000000-00000 · Cited by 21
Limsanon, T., & Kalayasiri, R. (2014) · Behavior Therapy · doi:10.1016/j.beth.2014.10.002 · Cited by 21
Cardiovascular effects of pharmacologic therapies for smoking cessation
Sobieraj, D. M., White, W. B., & Baker, W. L. (2012) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2012.11.003 · Cited by 21
A Review of Smoking Cessation in Bipolar Disorder: Implications for Future Research
George, T. P., Wu, B. S., & Weinberger, A. H. (2012) · Journal of Dual Diagnosis · doi:10.1080/15504263.2012.671717 · Cited by 21
Schnoll, R. A., Wileyto, E. P., & Lerman, C. E. (2011) · Addictive Behaviors · doi:10.1016/j.addbeh.2011.12.009 · Cited by 21
Metadata
- Authors
- Gonzales, D.
- Affiliations
- Oregon Health & Science University (US)
- Corresponding author
- Gonzales, David
- ORCID
- Gonzales, David
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2006-07-05
- Volume
- 296
- Issue
- 1
- Pages
- 47
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2107200746
- Cited by
- 1,361
- References
- 29
- Citations by year
- 2026: 32 · 2025: 21 · 2024: 25 · 2023: 25 · 2022: 34 · 2021: 26 · 2020: 52 · 2019: 49 · 2018: 41 · 2017: 51 · 2016: 50 · 2015: 70 · 2014: 74 · 2013: 80 · 2012: 94
- FWCI
- 85.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Oregon Health and Science University
- Cardinal Health
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- varenicline, bupropion sustained release, smoking cessation, α4β2 nicotinic acetylcholine receptor, partial agonists, nicotine dependence, continuous abstinence, exhaled carbon monoxide, brief counseling, nicotine replacement therapy, drug safety, adverse events, relapse, nicotine withdrawal symptoms, nicotine self-administration
- MeSH terms
- Varenicline, Adult, Benzazepines, Delayed-Action Preparations, Double-Blind Method, Female, Humans, Male, Middle Aged, Quinoxalines, Receptors, Nicotinic, Smoking Cessation, Bupropion, Nicotinic Agonists, Dopamine Uptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
